Beyond Air (XAIR) Stock Price, News & Analysis

Company Overview

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Key Stats

• Today's Range: $0.20 to $0.21
• 50-Day Range: $0.19 to $0.30
• 52-Week Range: $0.19 to $1.49
• Volume: 5.34 million shs
• Average Volume: 1.15 million shs
• Market Capitalization: $17.56 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.50
• Consensus Rating: Buy

Beyond Air Stock Analysis - MarketRank™

Beyond Air scored higher than 83% of companies evaluated by MarketBeat, and ranked 83rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Beyond Air has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Beyond Air has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Beyond Air are expected to grow in the coming year, from ($0.79) to ($0.42) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beyond Air is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beyond Air is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Beyond Air has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.98% of the float of Beyond Air has been sold short.

Short Interest Ratio / Days to Cover

Beyond Air has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Beyond Air has recently increased by 13.89%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beyond Air does not currently pay a dividend.

Dividend Growth

Beyond Air does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -0.91

Percentage of Shares Shorted

2.98% of the float of Beyond Air has been sold short.

Short Interest Ratio / Days to Cover

Beyond Air has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Beyond Air has recently increased by 13.89%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

7 people have searched for XAIR on MarketBeat in the last 30 days. This is an increase of 75% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Beyond Air to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Beyond Air insiders have bought more of their company's stock than they have sold. Specifically, they have bought $252,280.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

20.10% of the stock of Beyond Air is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 31.50% of the stock of Beyond Air is held by institutions.

XAIR Stock Analysis - Frequently Asked Questions

How have XAIR shares performed this year?

Beyond Air's stock was trading at $0.3585 at the beginning of 2025. Since then, XAIR stock has decreased by 43.3% and is now trading at $0.2033.
View the best growth stocks for 2025 here.

How were Beyond Air's earnings last quarter?

Beyond Air, Inc. (NASDAQ:XAIR) issued its quarterly earnings results on Monday, February, 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. Beyond Air had a negative net margin of 1,730.00% and a negative trailing twelve-month return on equity of 226.01%.
Read the conference call transcript.

How do I buy shares of Beyond Air?

Shares of XAIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Beyond Air own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Beyond Air investors own include Pfizer (PFE), NVIDIA (NVDA), General Motors (GM), Meta Platforms (META), Corbus Pharmaceuticals (CRBP), Norwegian Cruise Line (NCLH) and OPKO Health (OPK).

Company Calendar

• Last Earnings: 2/10/2025
• Today: 5/04/2025
• Next Earnings (Estimated): 6/23/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:XAIR
• CIK: 1641631
• Web: www.beyondair.net
• Phone: (516) 665-8200
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $1.50
• High Stock Price Target: $2.00
• Low Stock Price Target: $1.00
• Potential Upside/Downside: +637.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.06)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-60,240,000.00
• Net Margins: -1,730.00%
• Pretax Margin: -1,818.49%
• Return on Equity: -226.01%
• Return on Assets: -109.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.56
• Quick Ratio: 3.12

Sales & Book Value

• Annual Sales: $3.02 million
• Price / Sales: 5.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.27 per share
• Price / Book: 0.75

Miscellaneous

• Outstanding Shares: 86,370,000
• Free Float: 54,971,000
• Market Cap: $17.56 million
• Optionable: Optionable
• Beta: 0.25